Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...1718192021222324252627...170171»
  • ||||||||||  amiodarone / Generic mfg.
    Amiodarone Induced Type II Thyrotoxicosis in a Patient with Drug-resistant Atrial tachycardia (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2514;    
    Atrial fibrillation was currently being managed with metoprolol and rivaroxaban...Rate control was attempted with intravenous metoprolol and diltiazem drip however rate continued to be elevated...Although less common in the United States, clinicians should have an index of suspicion for Type II amiodarone induced thyrotoxicosis which can happen up to 30 months from discontinuation of amiodarone. Obtaining a through history and physical is essential and treatment requires prompt initiation of steroids.
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    Bilateral Adrenal Hemorrhage Following Deep Tissue Body Massage (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_1954;    
    Anticoagulant therapy and thromboembolic disease, as seen in our patient, are also risk factors. The atypical trauma induced by the patient's massage likely initiated the hemorrhagic event.
  • ||||||||||  rivaroxaban / Generic mfg.
    Multiple Reasons Of Secondary Hyperthyroidism and Unexpected Results (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_758;    
    When the patient was treated by rivaroxaban there was an unusual feature such as a hemoptysis, so the medicine was canceled... This case has shown that sometimes there are two reasons for development of secondary hyperthyroidism and only successive actions help to choose right way for diagnosis.
  • ||||||||||  Innohep (tinzaparin) / LEO Pharma
    Trial completion date, Trial primary completion date:  TILE: Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome (clinicaltrials.gov) -  May 10, 2023   
    P4,  N=60, Recruiting, 
    This case has shown that sometimes there are two reasons for development of secondary hyperthyroidism and only successive actions help to choose right way for diagnosis. Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Trial completion, Enrollment change:  RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding (clinicaltrials.gov) -  May 10, 2023   
    P2/3,  N=19, Completed, 
    Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Mar 2023 --> Mar 2024 Recruiting --> Completed | N=50 --> 19
  • ||||||||||  rivaroxaban / Generic mfg.
    Review, Journal:  Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease. (Pubmed Central) -  May 8, 2023   
    There was also no increase in the incidence of major bleeding with rivaroxaban in patients with CrCl < 30 mL/min. Taken together, these pharmacological and clinical data suggest that in patients with severe renal impairment, the approved dosages of rivaroxaban can be used in the treatment and prevention of VTE and for prophylaxis of DVT after hip or knee replacement surgery.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Plantar Vein Thrombosis in a Patient with COVID-19: Case Report. (Pubmed Central) -  May 7, 2023   
    Severe acute respiratory syndrome coronavirus 2 infection was suspected per clinical information and confirmed with reverse-transcriptase polymerase chain reaction technique. Treatment was successful using rivaroxaban and nonsteroidal antiinflammatory drugs.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Trial initiation date:  HIP Fracture Oral thromboPROphylaxis (Hip PRO Pilot) (clinicaltrials.gov) -  May 6, 2023   
    P3,  N=250, Not yet recruiting, 
    Treatment was successful using rivaroxaban and nonsteroidal antiinflammatory drugs. Initiation date: Mar 2023 --> Jun 2023
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Trial completion, Trial completion date:  Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients (clinicaltrials.gov) -  May 6, 2023   
    P4,  N=88, Completed, 
    Initiation date: Mar 2023 --> Jun 2023 Recruiting --> Completed | Trial completion date: Nov 2021 --> Feb 2023
  • ||||||||||  rivaroxaban / Generic mfg.
    Review, Journal:  Low dose rivaroxaban for the management of atherosclerotic cardiovascular disease. (Pubmed Central) -  May 6, 2023   
    Current guidelines recommend that low-dose rivaroxaban is given in an adjunct to standard therapy to patients with stable atherosclerosis and acute coronary syndromes at low bleeding risk. Several studies are underway to evaluate its putative benefits in other clinical settings.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Rivaroxaban Efficacy and Safety in (Pubmed Central) -  May 5, 2023   
    Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 No abstract available
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Effectiveness and Safety of Rivaroxaban (Pubmed Central) -  May 5, 2023   
    P=N/A
    No abstract available Among active cancer patients experiencing VTE and not at high risk of bleeding on DOACs, rivaroxaban was associated with a reduced risk of recurrent VTE versus LMWHs at 3 and 6
  • ||||||||||  Fraxiparine (nadroparin) / Aspen Pharma
    Journal, Head-to-Head, Surgery:  Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial. (Pubmed Central) -  May 4, 2023   
    In the safety analysis population, the incidence of any on-treatment bleeding events did not differ significantly between the groups (12.2% for rivaroxaban vs. 7.0% for nadroparin; relative risk [RR], 1.9; 95% CI, [0.9-3.7]; p?=?.08), including major bleeding (9.7% vs. 6.5%; RR, 1.6 [95% CI, 0.9-3.7]; p?=?.24), and nonmajor bleeding (2.6% vs. 0.5%; RR, 5.2 [95% CI, 0.6-45.2]; p?=?.13). Rivaroxaban for thromboprophylaxis after oncologic lung surgery was shown to be noninferior to nadroparin.
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion date, Trial primary completion date:  Rivaroxaban in Left Ventricular Thrombus (clinicaltrials.gov) -  May 3, 2023   
    P4,  N=320, Recruiting, 
    These associations differed according to the used drug, but this should be interpreted with cautious due to small sample sizes. Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Low-dose rivaroxaban: can cardiovascular events be reduced? (Pubmed Central) -  May 1, 2023   
    The rationale that can explain the improvement of cardiovascular outcome is that platelet aggregation and fibrin formation are involved in arterial thrombosis and rivaroxaban is able to target both ways and has a synergic effect with ASA. The aim of this review is to discuss the potential mechanisms and added benefits of DPI, in patients with PAD and CAD.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
    Journal, Adherence:  Direct oral anticoagulants: patient reported adherence and minor bleedings. (Pubmed Central) -  Apr 29, 2023   
    Minor bleedings were less common in the dabigatran group. The impact of minor bleedings on adherence and a possible relationship to clinical outcomes need to be further studied.
  • ||||||||||  PAC-1 / Vanquish Oncology
    Journal:  Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa. (Pubmed Central) -  Apr 28, 2023   
    The expression of P-selectin, the phosphorylation of myristoylated alanine-rich C kinase substrate by U46619 or ADP, and the activation of PAC-1 in platelets were inhibited by CSL...CSL demonstrated strong anticoagulant and antithrombotic effects in a mouse model of arterial and pulmonary thrombosis. Our findings suggest that CSL is a potential pharmacological candidate for a novel class of anti-FXa and antiplatelet medications.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., warfarin / Generic mfg.
    Journal:  Exploring the Clinical Efficacy of Venous Thromboembolism Management in Saudi Arabian Hospitals: An Insight into Patient Outcomes. (Pubmed Central) -  Apr 28, 2023   
    The results of the study highlight the need for further research to determine the most effective therapeutic strategy for VTE management in Saudi Arabian hospitals. The findings also suggest that anticoagulation therapy, including oral anticoagulants, may increase the risk of VTE recurrence, while thrombolytic therapy and catheter-directed thrombolysis may lower the risk.
  • ||||||||||  rivaroxaban / Generic mfg.
    PK/PD data, Journal, Real-world evidence, Real-world:  Population Pharmacokinetics of Rivaroxaban In Real-World Patients. (Pubmed Central) -  Apr 27, 2023   
    Several covariates influenced the CL of rivaroxaban and contributed toward this variability. The results may provide a guide that can aid the clinician during the initiation and adjustment of therapeutic regimens.